Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo.
In previous studies we have shown that combined chemo-immunotherapy of L1210 leukemia with IL-12 and doxorubicin results in striking anti-tumor effects producing 100% of long-term survivors. In this study we investigated the efficacy of a combination of IL-12 and mitoxantrone in murine L1210 leukemia. Mice inoculated with 1x105 leukemia cells were treated with a single dose of mitoxantrone and seven daily doses of IL-12, and were daily observed for survival. Treatment with IL-12 or mitoxantrone given alone produced moderate anti-leukemic effects. However, combination of both drugs resulted in a significant prolongation of mouse survival time. Importantly, there were almost 50% of long-term (>60 days) survivors among the mice treated with both agents. This therapeutic effect was completely abrogated by sub-lethal, whole-body X-irradiation, and significantly reduced after macrophage depletion.
Golab
J
J
Department of Immunology, Institute of Biostructure, The Medical University of Warsaw, Warsaw 02-004, Poland.
Zagozdzon
R
R
Kozar
K
K
Kaminski
R
R
Giermasz
A
A
Stoklosa
T
T
Lasek
W
W
Jakobisiak
M
M
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004357:Drug Synergism; D018664:Interleukin-12 / Q000008:administration & dosage*; D007939:Leukemia L1210 / Q000188:drug therapy*; D008264:Macrophages / Q000502:physiology; D051379:Mice; D008942:Mitoxantrone / Q000008:administration & dosage*
D018664:Interleukin-12; D008942:Mitoxantrone